Investing.com – U.S. stocks were higher after the close on Thursday, as gains in the Technology, Basic Materials and Consumer Services sectors led shares higher. At the close in...
Pre-Open Stock Movers: Biodesix, Inc. (NASDAQ:BDSX) 55% HIGHER; sees insider buying from the Chairman and other members of the board. Hoth Therapeutics, Inc. (NASDAQ:HOTH) 24%...
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) announced new positive phase I/II data for pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D), a rare genetic disease. The...
Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) announced top-line results from a phase III, multi-center study (MEDALIST). The MEDALIST study...
The Medicines Company (NASDAQ:MDCO) announced that Independent Data Monitoring Committee (IDMC) has recommended that the ongoing phase III studies (ORION) of its candidate,...
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company’s lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company’s preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
|Average||2.700 (+517.85% Upside)|
|No. of Analysts||5|